prasterone, intravaginal

Drug Overview

Prasterone (intravaginal) is an innovative medication within the Gynecology category. It belongs to the Drug Class of Steroid Hormones, specifically focusing on DHEA (dehydroepiandrosterone). This treatment is carefully designed to help women navigate the physical changes of menopause, specifically addressing the painful symptoms of vulvar and vaginal atrophy.

For many postmenopausal women, the natural drop in hormone levels can cause the vaginal tissues to become thin, dry, and easily irritated. Intravaginal prasterone offers a targeted approach to deeply nourish and restore these tissues, improving comfort and sexual health without the need for whole-body (systemic) hormone therapy.

Key Drug Information:

• Generic Name / Active Ingredient: Prasterone (synthetic DHEA).
• US Brand Names (Equivalents): Intrarosa.
• Route of Administration: Intravaginal insert (a small, daily suppository placed directly into the vagina).
• FDA Approval Status: Fully FDA-approved for use in postmenopausal women.

What Is It and How Does It Work? (Mechanism of Action)

Prasterone acts as a unique, locally acting Hormone Modulator. Instead of containing active estrogen or testosterone, it contains DHEA, which is an inactive “precursor” hormone.

At the molecular and hormonal level, this medication works through a process called intracrinology (local hormone production and action):

• Local Conversion: Once the prasterone insert melts inside the vagina, the DHEA is absorbed by the surrounding vaginal and vulvar cells. Inside these specific cells, enzymes naturally convert the DHEA into active estrogens and androgens (like testosterone).
• Receptor Activation and Tissue Repair: These newly formed hormones bind to estrogen and androgen receptors directly within the vaginal tissue. This dual-action stimulates the local cells to grow and divide.
• Restoring the Vaginal Environment: By promoting cellular growth, prasterone increases the thickness of the vaginal wall (more superficial cells) and reduces the number of fragile, thinning cells (parabasal cells). It also increases local glycogen production, which friendly vaginal bacteria turn into lactic acid. This safely lowers the vaginal pH back to a healthy, acidic, pre-menopausal state.
• Minimal Systemic Exposure: Because the hormone conversion happens entirely inside the vaginal cells, the active hormones are used and broken down locally. This means blood levels of estrogen and testosterone remain safely within the normal postmenopausal range, avoiding the effects of whole-body hormone therapy.

FDA-Approved Clinical Indications

Prasterone is specifically formulated to treat the local physical changes caused by the menopausal transition.

Primary Gynecological/Obstetric Indications

• Vulvar and Vaginal Atrophy (Dyspareunia): The primary, FDA-approved use is for the treatment of moderate to severe dyspareunia (pain during sexual intercourse) caused by vulvar and vaginal atrophy in postmenopausal women.

Off-Label / Endocrinological Indications

• Genitourinary Syndrome of Menopause (GSM): Used off-label to relieve other associated symptoms of GSM, such as severe vaginal dryness, burning, and irritation.
• Recurrent Urinary Tract Infections (UTIs): Because restoring the vaginal pH helps balance local bacteria, it is sometimes used off-label to help prevent recurrent UTIs in postmenopausal women.

Dosage and Administration Protocols

Prasterone is provided as a small, teardrop-shaped solid insert that melts at body temperature. It is inserted high into the vagina using a provided applicator or a clean finger.

Dose Adjustments and Special Populations:

• Renal/Hepatic Impairment: Because prasterone acts locally with minimal systemic absorption, no specific dose adjustments are required for patients with kidney or liver issues.
• History of Breast Cancer: While blood levels of estrogen remain low, breast cancer is a hormone-sensitive condition. Prasterone has not been fully studied in women with a history of breast cancer; therefore, these patients must consult their oncologist before use.

Clinical Efficacy and Research Results

Recent clinical studies (2020-2026) strongly validate the efficacy of intravaginal prasterone in reversing the physical signs of vaginal atrophy and relieving pain.

• Cellular Improvements: In 12-week clinical trials, postmenopausal women using 6.5 mg of prasterone daily experienced a significant anatomical shift. The percentage of healthy, thick superficial cells increased by approximately 10%, while fragile parabasal cells decreased by over 40%.
• pH Normalization: The vaginal pH safely decreased by an average of 0.8 to 1.0 units, returning the vaginal environment to a protective, acidic state (pH < 5.0).
• Pain Reduction: When measuring pain during sexual activity on a standard Visual Analog Scale (VAS) and standardized symptom questionnaires, patients reported a statistically significant reduction in dyspareunia severity compared to a placebo. Over 80% of patients reported meaningful improvements in sexual comfort and decreased vaginal dryness within 12 weeks.

Safety Profile and Side Effects

Unlike traditional systemic estrogen therapies, intravaginal prasterone does not carry a “Black Box Warning” for cardiovascular disease, stroke, or dementia. It is considered highly safe for its approved local use.

Common Side Effects (>10%)

• Vaginal Discharge: The most common side effect is a noticeable vaginal discharge, which is primarily the melted base of the insert mixed with normal vaginal secretions.
• Abnormal Pap Smear: Occasionally, patients may have atypical Pap smear results. This is often due to the rapid cellular changes and repair happening in the cervix and vagina, rather than an indication of cancer.

Serious Adverse Events

• Severe side effects, such as Venous Thromboembolism (VTE) or bone mineral density loss, are highly unlikely because the active hormones do not significantly enter the general bloodstream.
• Undiagnosed Bleeding: Any postmenopausal vaginal bleeding should be thoroughly investigated by a doctor to rule out endometrial cancer before starting or continuing this medication.

Management Strategies

• Managing Discharge: Patients are advised to wear a light panty liner during the day, as the medication is taken at bedtime and may cause morning discharge.
• Routine Screenings: Continue with standard, age-appropriate gynecological care, including routine pelvic exams and mammograms.

Research Areas

While prasterone acts as a direct Hormone Modulator, its ability to restore tissue health connects deeply with the principles of regenerative medicine. Current Research Areas in gynecology are exploring how local DHEA therapy can be combined with other regenerative modalities. For example, ongoing clinical trials are investigating the combined use of intravaginal prasterone with fractional CO2 lasers, radiofrequency treatments, or Platelet-Rich Plasma (PRP) therapy. The goal is to see if preparing the vaginal tissue with prasterone enhances the long-term tissue repair and collagen-building effects of these energy-based and regenerative devices, offering a comprehensive cure for severe Genitourinary Syndrome of Menopause (GSM).

Disclaimer: These studies regarding the combined use of intravaginal prasterone with energy-based devices or PRP for GSM are currently investigational and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• A comprehensive pelvic exam to confirm the diagnosis of vulvar and vaginal atrophy.
• Investigation of any unexplained postmenopausal bleeding (e.g., pelvic ultrasound or endometrial biopsy) before initiating treatment.
• Up-to-date mammogram and Pap smear as part of routine postmenopausal health maintenance.

Precautions During Treatment:

• Symptom Vigilance: Monitor for any unexpected spotting or bleeding and report it to a healthcare provider immediately.
• Hygiene: Ensure hands and the reusable applicator (if used) are washed thoroughly with soap and water before and after each use.

Do’s and Don’ts List:

• DO insert the medication at bedtime. Lying down helps prevent the melted insert from leaking out immediately.
• DO empty your bladder and wash your hands before inserting the medication.
• DON’T stop using the medication just because your symptoms improve. Vaginal atrophy is a chronic condition, and symptoms will likely return if the treatment is stopped.
• DON’T ignore any new or unusual vaginal bleeding. Always report this to your doctor.

Legal Disclaimer

The content provided in this guide is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, gynecologist, or other qualified healthcare provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.